OncRef

Clinical Trial: NCT05288205

Phase 1/2a Study of JAB-21822 Plus JAB-3312 in Patients With Advanced Solid Tumors Harboring KRAS p.G12C Mutation

Status:

RECRUITING

Phase:

Phase 1

Lead Sponsor:Allist Pharmaceuticals, Inc.
Information Provided By:Allist Pharmaceuticals, Inc.
Last Update Posted:2026-08-13

Study Overview

Brief Summary

This is a multicenter, open-label phase 1/2a study consisting of two parts: dose escalation phase and dose expansion phase. The objective of the dose escalation phase is to evaluate the safety, tolerability and pharmacokinetics of JAB-21822 in combination with JAB-3312 in patients with advanced solid tumors harboring KRAS p.G12C mutation and to determine the RP2D for the combination therapy. In the dose expansion phase, preliminary efficacy and safety of the combination therapy at the RP2D will be further explored in patients with specific cancer harboring KRAS p.G12C mutation.

Official Title

A Phase 1/2a Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Antitumor Activity of JAB-21822 in Combination With JAB-3312 in Patients With Advanced Solid Tumors Harboring KRAS p.G12C Mutation

Conditions

KRAS P.G12C, Non-small Cell Lung Cancer, Colorectal Cancer, Pancreatic Ductal Carcinoma

Intervention / Treatment

  • Drug: JAB-21822
  • Drug: JAB-3312

Other Study ID Numbers

  • JAB-21822-1006

Start Date (Actual)

2022-04-14

Primary Completion Date (Estimated)

2027-03

Study Completion Date (Estimated)

2027-03

Enrollment (Estimated)

240

Study Type

Interventional

Phase

Phase 1, Phase 2